Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs
- 1 May 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in HIV and AIDS
- Vol. 3 (3), 258-265
- https://doi.org/10.1097/coh.0b013e3282f85dc1
Abstract
This review summarizes recent developments regarding the unique clinical pharmacologic profile of nucleoside analog reverse transcriptase inhibitors for management of HIV. First, intracellular data in patients suggest that nucleoside reverse transcriptase inhibitor-triphosphates are compartmentalized in different cell types. Additionally, intracellular drug-drug interactions were identified, which were undetectable in plasma. Second, extracellular data illustrate multiple bidirectional plasma drug-drug interactions between renally eliminated tenofovir and liver-metabolized drugs. Definitive mechanistic details for these interactions are lacking but they appear to involve renal and/or enteric drug transporters. Furthermore, the plasma versus female genital tract disposition of these agents was recently elucidated, which is important for currently investigated indications for pre-exposure and post-exposure prophylaxis. Finally, tenofovir/emtricitabine and abacavir (using a promising human leukocyte antigen-B*5701 genetic test for hypersensitivity)/lamivudine have emerged as common first-line nucleoside analog reverse transcriptase inhibitors because of co-formulations, once-daily dosing, and favorable tolerability and adverse effect profiles. Nevertheless, elucidating the long-term safety profile for all nucleoside analog reverse transcriptase inhibitors remains a priority. Knowledge of nucleoside analog reverse transcriptase inhibitor disposition intracellularly and extracellularly has expanded. This provides a basis for rational use of these agents clinically and adds new perspectives for future research.Keywords
This publication has 43 references indexed in Scilit:
- Intracellular Pharmacokinetics of Once versus Twice Daily Zidovudine and Lamivudine in AdolescentsAntimicrobial Agents and Chemotherapy, 2007
- Effects of Human Immunodeficiency Virus Protease Inhibitors on the Intestinal Absorption of Tenofovir Disoproxil Fumarate In VitroAntimicrobial Agents and Chemotherapy, 2007
- Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxisAIDS, 2007
- Lopinavir/Ritonavir Pharmacokinetic Profile: Impact of Sex and Other Covariates Following a Change From Twice-Daily to Once-Daily TherapyThe Journal of Clinical Pharmacology, 2007
- Effect of Lamivudine on the Plasma and Intracellular Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2007
- Lipodystrophy in HIV 1-infected patients: lessons for obesity researchInternational Journal of Obesity, 2007
- Evidence and Possible Consequences of the Phosphorylation of Nucleoside Reverse Transcriptase Inhibitors in Human Red Blood CellsAntimicrobial Agents and Chemotherapy, 2007
- Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled TrialPLoS Clinical Trials, 2007
- Mechanism of Active Renal Tubular Efflux of TenofovirAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetics of Tenofovir Disoproxil Fumarate and Ritonavir-Boosted Saquinavir Mesylate Administered Alone or in Combination at Steady StateAntimicrobial Agents and Chemotherapy, 2006